Armetheon Announces European Medicines Agency’s Support for 1000 Patient Single Phase 3 Study prior to MAA Filing for its Novel Oral Anticoagulant Tecarfarin

MENIO PARK, Calif., Feb. 14, 2017 /PRNewswire/ – Armetheon, Inc., a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular diseases, today announced it has received advice from the European Medicines Agency (EMA) Scientific Advice Working Group (SAWG) for the development of its novel oral anticoagulant tecarfarin. The SAWG advised that Armetheon can conduct a single1000 patient pivotal study prior …

Armetheon announces issuance of a new U.S. patent for its Phase 2 clinical stage novel oral antiarrhythmic budiodarone

MENIO PARK, Calif., Feb. 13, 2017 – Armetheon, Inc., a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular diseases, today announced the issuance on January 24, 2017 by the U.S. Patent and Trademark Office (USPTO) of a new patent covering the company’s novel oral antiarrhythmic, budiodarone, the only known novel anti-arrhythmic in clinical development. The new U.S. Patent No. …

GONITRO™ to Participate in First-of-its-Kind 
Comparative Effectiveness ISCHEMIA Clinical Trial Sponsored by the National Institutes of Health

JACKSONVILLE, Fla. (Jan. 19, 2017) – Espero Pharmaceuticals, Inc., a commercial-stage cardiovascular pharmaceutical company, will donate GONITRO™ (nitroglycerin sublingual powder) to the ongoing International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) clinical trial and to the ISCHEMIA-Chronic Kidney Disease (CKD) ancillary trial. The company’s executives provided an update during last week’s annual JP Morgan Healthcare Conference …

Espero Pharmaceuticals Announces the Availability of FDA-Approved GONITRO™ (Nitroglycerin) Sublingual Powder in the U.S.

New Short-Acting Nitrate Powder Now Available in Single Dose Packets 
for Acute Relief of an Angina Pectoris Attack JACKSONVILLE, Fla. (Sept. 27, 2016) – Espero Pharmaceuticals Inc., a privately held specialty pharmaceutical company, today announced the commercial availability of GONITRO™ (nitroglycerin) sublingual powder for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. GONITRO™ …

Espero Pharmaceuticals Receives FDA Approval for GONITRO™ (Nitroglycerin) Sublingual Powder

JACKSONVILLE, Fla. (June 14, 2016) – Espero Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved GONITRO™ (nitroglycerin) sublingual powder for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. With this approval, GONITRO™ is the first and only short-acting nitrate in a …

Armetheon and Lee’s Pharma Enter into Agreement to Develop and Commercialize Tecarfarin in Greater China and Thailand

MILPITAS, Calif. and HONG KONG, Sept. 22, 2015 /PRNewswire/ – Armetheon, Inc., a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular diseases, today announced that Armetheon and China Cardiovascular Focus Limited, a subsidiary of Lee’s Pharmaceutical Holdings Limited (Lee’s Pharma), a public biopharmaceutical company listed on the main board of Hong Kong Stock Exchange (stock code: 950) with an …

Espero Pharmaceuticals Closes Seed Funding Round

JACKSONVILLE, FL – Espero Pharmaceuticals, Inc., (http://www.esperopharma.com) a privately held specialty pharmaceutical company, today announced the closing of a private round of funding as well as an equity investment made by G. Pohl-Boskamp GmbH & Co. KG (Pohl-Boskamp), a fully-integrated German pharmaceutical company with a 175 year operating history. Espero will use the proceeds to initiate commercialization activities as well …

Fierce Biotech: Armetheon raises $24M to get its anticoagulant into Phase III

By Damian Garde February 5, 2015 Menlo Park, CA’s Armetheon raised a $24.3 million B round to support work on a new oral blood thinner the biotech believes can fill a hole in the blockbuster anticoagulant market. The drug, tecarfarin, works by blocking an enzyme called VKOR that plays a role in blood clotting. In its Phase II trials, the …

Armetheon Completes $7.0 Million Series A Financing

Company poised to enter final pivotal trial for novel oral anti-coagulant Menlo Park, CA, August 28, 2014 –  Armetheon, Inc. (www.armetheon.com), a biopharmaceutical company focused on developing novel mid- to late-stage cardiovascular drug candidates, today announced that it has raised $7.0 million in its first round of financing. The Series A round was co-led by AshHill Biomedical Investments and Hercules Bioventures with …